UNH Filings — UnitedHealth Group Incorporated - FilingSpy
UNH
UnitedHealth Group Incorporated
A healthcare giant that runs two big businesses: UnitedHealthcare, which provides health insurance to employers, individuals, and government programs, and Optum, which delivers value-based care, pharmacy benefits, analytics, and technology to health systems and plans. Its Optum Rx arm manages prescription drug spending through a network of tens of thousands of retail pharmacies and home delivery, while Optum Bank offers health financial services.
UnitedHealth's Q2 2026 operating income rose 55% to $8.0B as favorable reserve development offset a 1.6M membership decline.
rebounded sharply from a year ago, but the business is shrinking. was flat at $112.0B and operating income rose 55% to $8.0B, driven almost entirely by and cost management rather than growth, as shed 1.6 million members. The company is earning more from fewer people, a dynamic that depends on reserves that have already been set.
Key takeaways
rose 55% to $8.0B, while rose 61% to $5.5B and rose 61.5% to $6.04.
The improved 2.7 percentage points to 86.7%, driven by and affordability initiatives, partially offset by elevated medical cost trends.
served 1.6 million fewer people than a year ago, with declines of 9% in both and Medicaid, as the company continued benefit design changes, pricing actions, and exited one state.
Section summaries
Management's Discussion and Analysis
Q2 2026 earnings from operations rose 55% to $8.0B, driven by favorable prior-period reserve development and cost management, while membership contracted across Medicare Advantage, Medicaid, and commercial risk-based plans.
⌄
Consolidated earnings from operations increased 55% to $8.0 billion, with attributable to common shareholders up 61% to $5.5 billion.
fell 5% on fewer patients in arrangements, but operating earnings rose 177% on cost management and increased favorable reserve development.
for the first half reached $20.0B, up $7.3B from a year earlier, supported by higher earnings and favorable dynamics.
The company repurchased 10.5 million shares for $1.6B during the quarter and completed a $1.5B acquisition on July 2, 2026, with an additional $1.5B payable within one year.
What changed
The Q1 2026 watch item on the was answered: the ratio rose 2.8 points sequentially to 86.7% from 83.9%, as the favorable reserve development that helped Q1 continued but was partly offset by elevated medical cost trends.
membership declined further: after a 1.1M drop in Q1 2026, the decline widened to 1.6M, confirming the contraction the company flagged in its FY 2025 10-K.
swung from a 15% decline in Q1 2026 to a 177% increase in Q2 2026, as cost management and favorable reserve development more than offset the continued 5% decline.
The $3.0B in pending acquisitions flagged in Q1 2026 partially closed, with a $1.5B acquisition completed on July 2, 2026 and another $1.5B payable within one year.
What to watch
Q3 2026 as elevated medical cost trends persist and the contribution from may not repeat at the same magnitude.
membership trajectory after the 1.6M decline, particularly whether and Medicaid contraction continues into 2027.
and patient volume in arrangements after a second consecutive quarter of 5% revenue decline.
Any loss estimate from the pending DOJ Medicare risk-adjustment whistleblower case, which remains unresolved with no loss estimable.
The improved 270 to 86.7%, primarily due to favorable prior-period reserve development and affordability initiatives, partially offset by elevated medical cost trends.
served 1.6 million fewer people, with declines of 9% in both Medicare Advantage and Medicaid, driven by benefit design changes, pricing actions, and the exit from one state.
's fell 5% due to fewer patients in , but earnings from operations rose 177% on cost management and increased favorable reserve development.
Cash flows from operations for the first half of 2026 reached $20.0 billion, up $7.3 billion , supported by higher earnings and favorable dynamics.
The company completed a $1.5 billion acquisition on July 2, 2026, with an additional $1.5 billion payable within one year, and repurchased 10.5 million shares for $1.6 billion during the period.
Quantitative and Qualitative Disclosures About Market Risk
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap…
⌄
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2026 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
June 30, 2026
Increase (Decrease) in Market Interest Rate Investment Income Per Annum Interest Expense Per Annum Fair Value of Financial Assets Fair Value of Financial Liabilities
2 % $ 786 $ 569 $ (4,386) $ (8,511)
1 393 284 (2,237) (4,639)
(1) (393) (271) 2,271 5,622
(2) (786) (537) 4,550 12,478
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
⌄
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2…
⌄
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2025 10-K.